Afimmune - pioneering drug discovery

About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with diseases for which existing therapies are ineffective or unsafe. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

September 23, 2020

Published by Adelle McGourty at September 23, 2020

Afimmune Initiates Epeleuton Phase IIb TRIAGE Study in Patients With High Triglycerides and Type 2 Diabetes

Data from Phase IIa show potent effect of Epeleuton on Triglyceride and HbA1C levels Dublin, Ireland, 23rd September 2020 – Afimmune, a clinical stage drug discovery […]

November 14, 2019

Published by Adelle McGourty at November 14, 2019

Clinical Data Showing The Potential Of Epeleuton As A Treatment For Hypertriglyceridemia And Diabetes As Well As Cardiovascular Disease Prevention Will Be Presented At The American Heart Association’s 2019 Scientific Sessions, November 16-18

Dublin, Ireland, 14th November 2019 – Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]

More Press Releases

Join our mailing list

Contact us

t: +353 1 2946380 e: [email protected]

Latest Publications

August 11, 2020

Published by micadmin at August 11, 2020

Effects of Epeleuton, a Novel Synthetic Second‐Generation n‐3 Fatty Acid, on Non‐Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

The Epeleuton Phase 2a data was accepted for publication in the peer reviewed Journal of the American Heart Association. The paper can be found here. In […]